ArticleThe EMBO journal2000
The luminal part of the murine cytomegalovirus glycoprotein gp40 catalyzes the retention of MHC class I molecules.
Article in The EMBO journal, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 93 citations in OpenAlex.
- The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Review
- Targeting MHC-I inhibitory pathways for cancer immunotherapy.Trends in immunology · 2024Review
- The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors.International journal of molecular sciences · 2023Review
- Review
- Review
- Modulation of innate and adaptive immunity by cytomegaloviruses.Nature reviews. Immunology · 2020Review
- Positive Role of the MHC Class-I Antigen Presentation Regulator m04/gp34 of Murine Cytomegalovirus in Antiviral Protection by CD8 T Cells.Frontiers in cellular and infection microbiology · 2020Article
- The herpesviral antagonist m152 reveals differential activation of STING-dependent IRF and NF-κB signaling and STING's dual role during MCMV infection.The EMBO journal · 2019Article
- Present Yourself! By MHC Class I and MHC Class II Molecules.Trends in immunology · 2016Review
- A Novel MHC-I Surface Targeted for Binding by the MCMV m06 Immunoevasin Revealed by Solution NMR.The Journal of biological chemistry · 2015Article
- An endocytic YXXΦ (YRRF) cargo sorting motif in the cytoplasmic tail of murine cytomegalovirus AP2 'adapter adapter' protein m04/gp34 antagonizes virus evasion of natural killer cells.Medical microbiology and immunology · 2015Article
- A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- The p36 isoform of murine cytomegalovirus m152 protein suffices for mediating innate and adaptive immune evasion.Viruses · 2013Article
- Murine cytomegalovirus immune evasion proteins operative in the MHC class I pathway of antigen processing and presentation: state of knowledge, revisions, and questions.Medical microbiology and immunology · 2012Review
- Human cytomegalovirus US3 modulates destruction of MHC class I molecules.Molecular immunology · 2012Article
- All is fair in virus-host interactions: NK cells and cytomegalovirus.Trends in molecular medicine · 2011Article
- Temporal profiling of the coding and noncoding murine cytomegalovirus transcriptomes.Journal of virology · 2011Article
- Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response.Frontiers in immunology · 2011Article
- Direct interaction of the mouse cytomegalovirus m152/gp40 immunoevasin with RAE-1 isoforms.Biochemistry · 2010Article
- Differential susceptibility of RAE-1 isoforms to mouse cytomegalovirus.Journal of virology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Murine cytomegalovirus (MCMV) interferes with the MHC class I pathway of antigen presentation. The type I transmembrane glycoprotein gp40, encoded by the gene m152, retains major histocompatibility complex (MHC) class I complexes in the endoplasmic reticulum (ER)-Golgi intermediate compartment (ERGIC)/cis-Golgi. These MHC class I complexes are stable, show an extended half-life and do not exchange beta(2)-microglobulin, whereas gp40 reaches an endosomal/lysosomal compartment where it subsequently is degraded. The analysis of regions within the viral protein that are essential for MHC class I retention revealed that a secreted form of gp40, lacking the cytoplasmic tail and the transmembrane region, still has the capacity to retain MHC class I complexes. Continuous expression of gp40 is not required for MHC class I retention. Our data indicate that the retention of MHC class I complexes in the ERGIC/cis-Golgi is triggered by gp40 and does not require the further presence of the viral protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.